Socure raised $156M at a $5.2B valuation and bought agentic-AI startup Fravity to fight machine-speed fraud with AI agents of its own.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
Google's custom-chip deal could hand Marvell up to $120 billion in revenue. So why did the stock drop 7% on record earnings? The payoff doesn't land until fiscal 2029.
Gatik raised a $200M Series D led by Qatar Investment Authority and Koch to scale its driverless middle-mile trucks — with $600M in freight already contracted.
Instinct's personal AI agent hit a $2.5B valuation on a $250M Series B, up 50x in four months — as security experts flag its perpetual grip on your inbox.
Socure raised $156M at a $5.2B valuation and bought agentic-AI startup Fravity to fight machine-speed fraud with AI agents of its own.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
